Dr Michael Winlo recently sat down with Elisha Newell at Proactive on the back of news that Emyria has received ethics approval for Phase 3 clinical trials of EMD-RX5.

As Dr Winlow discusses, a successful trial is a next step in potentially registering EMD-RX5 with the Therapeutic Goods Administration as an over-the-counter treatment for Australians experiencing psychological distress.

You can watch the interview here: Emyria approved to start Phase 3 clinical trial of EMD-RX5